Carmat Fails to Meet Heart-Device Goals as Stock Holds Up

Carmat SAS, the medical-device maker whose shares soared more than sixfold in 2 1/2 years, said in 2011 it expected its experimental artificial heart to be sold in Europe this year. As it turns out, it’s not even close.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.